Anaptysbio Stock Performance
| ANAB Stock | USD 43.80 1.41 3.12% |
On a scale of 0 to 100, AnaptysBio holds a performance score of 12. The firm shows a Beta (market volatility) of -0.2, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning AnaptysBio are expected to decrease at a much lower rate. During the bear market, AnaptysBio is likely to outperform the market. Please check AnaptysBio's information ratio, treynor ratio, and the relationship between the downside deviation and total risk alpha , to make a quick decision on whether AnaptysBio's price patterns will revert.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in AnaptysBio are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, AnaptysBio sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (3.12) | Five Day Return (9.28) | Year To Date Return (2.56) | Ten Year Return 157.65 | All Time Return 157.65 |
1 | AnaptysBio, Inc. Expected to Beat Earnings Estimates What to Know Ahead of Q3 Release | 10/28/2025 |
2 | AnaptysBio price target lowered by 20 at Wedbush ANAB | 11/10/2025 |
3 | AnaptysBio announces 100M share repurchase program ANAB | 11/21/2025 |
4 | SMT Corp Expands ISOIEC 17025 and SAE AS6171 Accreditations to UK Laboratory, Strengthening Global Counterfeit Detection Capabilities | 12/08/2025 |
5 | Disposition of 6360 shares by Dennis Mulroy of AnaptysBio at 45.2062 subject to Rule 16b-3 | 12/16/2025 |
6 | Disposition of 10000 shares by Eric Loumeau of AnaptysBio at 46.0 subject to Rule 16b-3 | 12/17/2025 |
7 | This Biotech Stock Has More Than Tripled in 2025, but Red Flags Are Waving | 12/19/2025 |
8 | Disposition of 10000 shares by Eric Loumeau of AnaptysBio at 51.0 subject to Rule 16b-3 | 12/22/2025 |
9 | Disposition of 11068 shares by Schmid John P. of AnaptysBio at 51.0 subject to Rule 16b-3 | 12/23/2025 |
10 | Disposition of 1500 shares by Lizzul Paul F. of AnaptysBio at 50.0 subject to Rule 16b-3 | 12/26/2025 |
11 | AnaptysBio stock hits 52-week high at 51.58 - Investing.com | 12/29/2025 |
12 | Disposition of 7287 shares by Eric Loumeau of AnaptysBio subject to Rule 16b-3 | 01/02/2026 |
13 | Disposition of 2983 shares by Eric Loumeau of AnaptysBio at 43.26 subject to Rule 16b-3 | 01/05/2026 |
14 | Acquisition by Orwin John A of 6000 shares of AnaptysBio subject to Rule 16b-3 | 01/06/2026 |
15 | Anaptys Files Motion to Dismiss Tesaros Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary | 01/08/2026 |
| Begin Period Cash Flow | 36 M | |
| Total Cashflows From Investing Activities | 95.4 M |
AnaptysBio | Build AI portfolio with AnaptysBio Stock |
AnaptysBio Relative Risk vs. Return Landscape
If you would invest 3,246 in AnaptysBio on October 11, 2025 and sell it today you would earn a total of 1,134 from holding AnaptysBio or generate 34.94% return on investment over 90 days. AnaptysBio is currently generating 0.5444% in daily expected returns and assumes 3.4505% risk (volatility on return distribution) over the 90 days horizon. In different words, 30% of stocks are less volatile than AnaptysBio, and 90% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
AnaptysBio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for AnaptysBio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as AnaptysBio, and traders can use it to determine the average amount a AnaptysBio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1578
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ANAB | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average AnaptysBio is performing at about 12% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of AnaptysBio by adding it to a well-diversified portfolio.
AnaptysBio Fundamentals Growth
AnaptysBio Stock prices reflect investors' perceptions of the future prospects and financial health of AnaptysBio, and AnaptysBio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on AnaptysBio Stock performance.
| Return On Equity | -3.08 | ||||
| Return On Asset | -0.0423 | ||||
| Profit Margin | (0.50) % | ||||
| Operating Margin | 0.45 % | ||||
| Current Valuation | 1.02 B | ||||
| Shares Outstanding | 27.69 M | ||||
| Price To Earning | 81.21 X | ||||
| Price To Book | 114.73 X | ||||
| Price To Sales | 7.46 X | ||||
| Revenue | 91.28 M | ||||
| Gross Profit | 16.47 M | ||||
| EBITDA | (92.74 M) | ||||
| Net Income | (145.23 M) | ||||
| Cash And Equivalents | 442.15 M | ||||
| Cash Per Share | 15.66 X | ||||
| Total Debt | 369.46 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 22.79 X | ||||
| Book Value Per Share | (1.07) X | ||||
| Cash Flow From Operations | (135.34 M) | ||||
| Earnings Per Share | (2.82) X | ||||
| Market Capitalization | 1.26 B | ||||
| Total Asset | 483.83 M | ||||
| Retained Earnings | (759.33 M) | ||||
| Working Capital | 386.45 M | ||||
| Current Asset | 297.84 M | ||||
| Current Liabilities | 16.6 M | ||||
About AnaptysBio Performance
By analyzing AnaptysBio's fundamental ratios, stakeholders can gain valuable insights into AnaptysBio's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if AnaptysBio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if AnaptysBio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.27) | (0.28) | |
| Return On Capital Employed | (0.24) | (0.25) | |
| Return On Assets | (0.27) | (0.28) | |
| Return On Equity | (1.84) | (1.94) |
Things to note about AnaptysBio performance evaluation
Checking the ongoing alerts about AnaptysBio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for AnaptysBio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| AnaptysBio appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 91.28 M. Net Loss for the year was (145.23 M) with profit before overhead, payroll, taxes, and interest of 16.47 M. | |
| AnaptysBio currently holds about 442.15 M in cash with (135.34 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 15.66. | |
| Over 94.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from globenewswire.com: Anaptys Files Motion to Dismiss Tesaros Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary |
- Analyzing AnaptysBio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether AnaptysBio's stock is overvalued or undervalued compared to its peers.
- Examining AnaptysBio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating AnaptysBio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of AnaptysBio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of AnaptysBio's stock. These opinions can provide insight into AnaptysBio's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for AnaptysBio Stock analysis
When running AnaptysBio's price analysis, check to measure AnaptysBio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AnaptysBio is operating at the current time. Most of AnaptysBio's value examination focuses on studying past and present price action to predict the probability of AnaptysBio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AnaptysBio's price. Additionally, you may evaluate how the addition of AnaptysBio to your portfolios can decrease your overall portfolio volatility.
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |